Literature DB >> 17142723

Cutting Edge: Programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens.

Natalia Martin-Orozco1, Yi-Hong Wang, Hideo Yagita, Chen Dong.   

Abstract

Constitutive presentation of tissue Ags by dendritic cells results in tolerance of autoreactive CD8+ T cells; however, the underlying molecular mechanisms are not well understood. In this study we show that programmed death (PD)-1, an inhibitory receptor of the CD28 family, is required for tolerance induction of autoreactive CD8+ T cells. An antagonistic Ab against PD-1 provoked destructive autoimmune diabetes in RIP-mOVA mice expressing chicken OVA in the pancreatic islet cells, which received naive OVA-specific CD8+ OT-I cells. This effect was mediated by the PD ligand (PD-L) PD-L1 but not by PD-L2. An increased number of effector OT-I cells recovered from the pancreatic lymph nodes of anti-PD-L1-treated mice showed down-regulation of PD-1. Furthermore, the blockade of PD-1/PD-L1 interaction during the priming phase did not significantly affect OT-I cell division but enhanced its granzyme B, IFN-gamma, and IL-2 production. Thus, during the presentation of tissue Ags to CD8+ T cells, PD-1/PD-L1 interaction crucially controls the effector differentiation of autoreactive T cells to maintain self-tolerance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17142723     DOI: 10.4049/jimmunol.177.12.8291

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  66 in total

1.  PD-1 signalling in CD4(+) T cells restrains their clonal expansion to an immunogenic stimulus, but is not critically required for peptide-induced tolerance.

Authors:  Joanne E Konkel; Friederike Frommer; Melanie D Leech; Hideo Yagita; Ari Waisman; Stephen M Anderton
Journal:  Immunology       Date:  2010-01-27       Impact factor: 7.397

2.  PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1.

Authors:  Marguerite Ghiotto; Laurent Gauthier; Nacer Serriari; Sonia Pastor; Alemseged Truneh; Jacques A Nunès; Daniel Olive
Journal:  Int Immunol       Date:  2010-06-29       Impact factor: 4.823

3.  BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.

Authors:  J Wang; Y Jia; S Zhao; X Zhang; X Wang; X Han; Y Wang; M Ma; J Shi; L Liu
Journal:  Oncogene       Date:  2017-07-17       Impact factor: 9.867

Review 4.  Inhibitory costimulation and anti-tumor immunity.

Authors:  Natalia Martin-Orozco; Chen Dong
Journal:  Semin Cancer Biol       Date:  2007-06-23       Impact factor: 15.707

5.  Local blockade of epithelial PDL-1 in the airways enhances T cell function and viral clearance during influenza virus infection.

Authors:  Beth McNally; Fang Ye; Meredith Willette; Emilio Flaño
Journal:  J Virol       Date:  2013-09-25       Impact factor: 5.103

6.  Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway.

Authors:  Fabienne Haspot; Thomas Fehr; Carrie Gibbons; Guiling Zhao; Timothy Hogan; Tasuku Honjo; Gordon J Freeman; Megan Sykes
Journal:  Blood       Date:  2008-06-24       Impact factor: 22.113

7.  LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L.

Authors:  Carrie L Lucas; Creg J Workman; Semir Beyaz; Samuel LoCascio; Guiling Zhao; Dario A A Vignali; Megan Sykes
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

Review 8.  T Follicular Regulatory Cells and Antibody Responses in Transplantation.

Authors:  Elizabeth F Wallin
Journal:  Transplantation       Date:  2018-10       Impact factor: 4.939

9.  Regulation of the induction and function of cytotoxic T lymphocytes by natural killer T cell.

Authors:  Hiroyasu Ito; Mitsuru Seishima
Journal:  J Biomed Biotechnol       Date:  2010-05-19

10.  B7-H1-deficiency enhances the potential of tolerogenic dendritic cells by activating CD1d-restricted type II NKT cells.

Authors:  Carolin Brandl; Sonja Ortler; Thomas Herrmann; Susanna Cardell; Manfred B Lutz; Heinz Wiendl
Journal:  PLoS One       Date:  2010-05-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.